Marvel Biosciences Targets Alzheimer’s with New Study Insights

Marvel Biosciences Corp (TSE:MRVL) has released an update.

Marvel Biosciences Corp. has underscored the significance of a study led by scientific board member, Professor David Blum, which links early increases in adenosine A2A receptors in neurons to memory loss in Alzheimer’s disease models. The research, which diverges from traditional focuses on amyloid plaques, points to Tau phosphorylation as a major factor in cognitive deficits, supporting the potential of Marvel’s A2aR antagonist, MB204, as a promising treatment for Alzheimer’s.

For further insights into TSE:MRVL stock, check out TipRanks’ Stock Analysis page.